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Abstract
Malaria is a global public health issue. Despite the efforts in malaria prevention, 
nearly half the world’s population is at risk of infection. Until present-day, research-
ers are struggling to design and discover an efficacious antimalarial. In comparison 
to most common antimalarial chemotypes that eliminate erythrocytic stages of P. 
falciparum, 4(1H)-quinolones and 4(1H)-pyridones exhibit antimalarial activity 
against multiple stages of the parasite. They have potential to treat blood stages of 
multidrug resistant P. falciparum malaria, eradicate dormant exoerythro stages of 
relapsing malaria species (P. vivax), and prevent transmission of infectious game-
tocytes to mosquitoes. However, thus far, the advancement of these chemotypes 
towards pre-clinical and clinical development has been impeded due to poor physi-
cochemical properties, poor oral bioavailability, and poor dose-proportionality 
limiting preclinical safety and toxicity studies. Despite all these challenges, 4(1H)-
quinolones and 4(1H)-pyridones continue to be at the forefront for the development 
of the next-generation antimalarials as they would have tremendous global public 
health impact and could significantly enhance current malaria elimination efforts.




Malaria is a global, mosquito-borne, parasitic disease that is serious and fatal, 
putting people of 87 countries at risk. The population with the highest risk of 
infection are young children under the age of five and pregnant women living in the 
sub-Saharan Africa. In 2020, the World Health Organization (WHO) reported an 
estimate of 229 million malaria cases, with approximately 409,000 deaths in 2019 
alone [1]. This is a significant decrease from that of ten years ago, where the global 
number of malaria cases and deaths were 243 million and 863,000, respectively. The 
increased efforts in malaria prevention had led to these decreases in cases [2].
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Malaria is a disease caused by a protozoan parasite of the genus Plasmodium. 
These species are P. falciparum, P. vivax, P. knowlesi, P. malariae, and P. ovale, of 
which P. falciparum is the most common species of transmission [3, 4].
To develop efficacious antimalarial drugs, it is important to understand the 
Plasmodium lifecycle via its route of infection. Initially, the disease is transmitted 
into the host via a pregnant, female Anopheles mosquito when it takes a bloodmeal 
to feed her eggs by simultaneously injecting sporozoites and an anticoagulant to 
prevent blood clotting. Those that penetrate the blood vessels enter the bloodstream 
and head to the hepatocytes. The parasites entry point to the hepatocytes requires 
the penetration of the liver sinusoidal barrier, consisting of sentinel Kupffer 
cells [4].
Once Plasmodium sporozoites invade the hepatocytes, they do not mature 
immediately within the first invaded hepatocyte. They migrate through several 
hepatocytes, causing necrosis. When the parasite settles, these develop into the 
liver schizont form. Liver schizont is a multinucleate state of the cell during asexual 
reproduction called schizogony. One infected liver cell can develop into thousands 
of merozoites. These merozoites are released into the bloodstream when the hepa-
tocytes bursts. Once these merozoites are released into the bloodstream, they will 
invade the erythrocytes through specific ligand-receptor interactions mediated by 
the proteins on the surfaces of the parasite and the erythrocyte [3, 5, 6].
Once inside the erythrocytes, the parasites can hide from the hosts’ immune 
response. These merozoites begins to enlarge and become a uninucleate cell 
termed trophozoite. The nucleus of the trophozoites divides asexually to produce 
a schizont. The schizont then divides and produces merozoites. These merozoites 
can invade other erythrocytes and continue replicating. The clinical symptoms of 
malaria appear when these erythrocytes rupture and releases merozoites [3].
After many rounds of schizogony in the erythrocyte, some merozoites, rather 
than replicating, enter a sexual phase, where they develop into male and female 
gametocytes. Erythrocytes containing gametocytes do not rupture. Gametocytes 
are incapable of forming gametes within their hosts and form only when they 
are taken up by a mosquito. The importance of sexual differentiation is that it is 
responsible for the transmission from host to the Anopheles mosquito. The male and 
female gametocytes fuse within the mosquito, which forms a diploid zygote that 
becomes an ookinete. These ookinetes migrate to the midgut of the mosquito, pass 
through the gut wall, and form oocysts. The meiotic division of the oocysts occur 
and form sporozoites, which migrate to the salivary glands of the mosquito. This 
mosquito then injects these sporozoites to the next host, completing the transmis-
sion cycle [3].
Opposed to the common P. falciparum infection, P. vivax can infect the liver cells 
and remain dormant for as long as several years by remaining in the hepatocytes as 
hypnozoites, rather than developing into liver schizonts. This is the cause of malaria 
relapse (Figure 1) [7].
Unfortunately, this infection follows a vicious, never-ending cycle between 
human and mosquito, if a cure is not discovered for all forms of the parasite. Hence, 
the life cycle dictates design consideration from the onset of the discovery, optimi-
zation, and development of a new antimalarial agent.
1.2 Past and present antimalarial drugs
Decline in malaria cases are being observed due to the increased efforts in 
preventing, controlling, and treating malaria [8]. Still, chemotherapy is the most 
common method of prevention and treatment utilized for this infection. Of course, 
given the complex nature of the parasite, these drugs act differently towards 
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different stages of the parasite. For this reason, antimalarials are categorized by 
their activity – blood schizonticidal, tissue schizonticidal, gametocytocidal, and 
sporontocidal drugs. Blood schizonticidal drugs are antimalarials that target the 
asexual erythrocytic stages of the parasite. Tissue schizonticidal drugs are antima-
larials that target hypnozoites. Gametocytocidal drug are antimalarials that targets 
the sexual erythrocytic forms of the parasite in the blood. Lastly, sporontocidal 
drugs are antimalarials that prevent formation of malarial oocytes and sporozoites 
in infected mosquito (Table 1) [9, 10].
Quinine (1), the first medicine to treat malaria, is an alkaloid isolated from the 
bark of Cinchona trees, which targets the asexual and sexual blood stage (Figure 2). 
This initial discovery in the 17th century of a natural product with antimalarial 
activity was revolutionary, as it was the first successful use of a chemical compound 
to treat an infectious disease. Unfortunately, due to its toxic nature and its rise of 
resistant P. falciparum strain, 1 was abandoned [11, 12]. However, its structure 
became the inspiration for the development of current antimalarials [13].
Currently, the majority of drugs target the asexual blood stages of the parasite. 
The most utilized drugs are chloroquine (2), artemisinin (3), and mefloquine 
(4) (Figure 2). Mefloquine (4), discovered during World War II, is a highly 
effective against blood stages of all Plasmodium spp. that affects humans [14, 15]. 
Chloroquine (2), initially discovered during the 1930s, was deemed toxic. However, 
with re-evaluation in the 1940s, chloroquine (2) became the standard medication 
for the treatment of malaria. Given its many advantages, such as excellent bioavail-
ability, low cost, low toxicity, and effectiveness, chloroquine (2) was predominately 
Figure 1. 
Schematic representation of the malaria life cycle.
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used for at least two decades [15, 16]. Artemisinin (3), discovered in 1972, is a 
natural product isolated from Artemisia annua (sweet wormwood) and has been 
used as an antimalarial drug in China [15]. However, our supply of varying anti-
malarial is very limited, where we do not have many that target beyond the blood 
stage. Primaquine (5) and atovaquone (6) are the commonly utilized drug against 
liver stage parasites (Figure 2). Primaquine (5) has restricted use because it poses 
a major health concern, as it causes haemolysis for those with glucose-6-phosphate 
dehydrogenase (G6PD) deficiency. G6PD deficiency is an X-linked abnormality 
that is very common in tropical areas, where malaria is most prevalent [17].
Not only is the inadequate number of antimalarials that are active against the 
different life stages of parasite an issue, the development of resistance towards cur-
rently available drugs is a major concern. Resistance towards current antimalarial 
drugs are usually a result of a point mutation that can decrease drug accumulation 
through altered influx/efflux mechanism or change the affinity of the drug to 
its’ validated targets [18, 19]. Actions have been taken by the WHO to act against 
resistance. Originally, artemisinin (3) was used as a monotherapy; however, given 
the relatively high recrudescence rate of approximately ten percent and the need 
for a seven-day course, this drug is now recommended by the WHO to be used in 
combination with another antimalarial. This is known as artemisinin combination 
Figure 2. 







Chloroquine (+) (−) (−) (−)
Quinine (+) (−) (+) (−)
Primaquine (−) (+) (+) (+)
Artemisinin (+) (−) (+) (−)
Atovaquone (+) (+) (−) (−)
Mefloquine (+) (−) (−) (−)
Table 1. 
Antimalarials targeting different forms of parasite.
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therapy (ACT). With the ACT, the treatment length is three days, which prevents 
the emergence of resistant strains [20, 21]. ACTs are a combination of drugs that 
have separate mechanism of action against the same stage of the parasite. In other 
words, ACTs would combine fast-acting artemisinin derivative antimalarial with a 
slow-acting, structurally different antimalarial. This enables the fast-acting anti-
malarial to quickly reduce the parasite burden as the slow-acting antimalarial will 
completely eliminate the remaining parasite population [22].
Despite these efforts, increased resistance from mutant strains of Plasmodium 
spp. and inadequate number of antimalarials have urged the need of novel antima-
larials that are active against multi-drug resistant strains for different forms of the 
parasite.
1.3 Recommended candidate profiles for the next generation of antimalarials
We are currently facing issues with current antimalarials due to resistant strains 
and lack of antimalarials to combat this problem. To develop the next generation 
of antimalarials, a description of the desired drug profile has been summarized in 
a Target Product Profile (TPP). TPPs are divided into different target candidate 
profiles (TCPs) since malaria chemotherapies will exist as combination therapy, 
containing more than one active ingredient. The main considerations across all 
TCPs are that these drugs are safe, affordable, and efficacious against multi-drug 
resistant Plasmodium spp. [23, 24].
2. Development of 4(1H)-quinolones and 4(1H)-pyridones
Abiding to the TCPs to develop a novel class of antimalarials is the current 
measure taken to assist in the eradication of malaria. 4(1H)-quinolones and 4(1H)-
pyridones are a promising class of antimalarials, exhibiting potent activity [25, 26]. 
Structurally, 4(1H)-quinolones and 4(1H)-pyridones are synthetic compounds that 
contain the common ring, making them distinctive (Figure 3).
Previously discovered 4(1H)-quinolones and 4(1H)-pyridones with antima-
larial activity in either avian, rodent, or primate were quickly abandoned without 
adequate evaluation. Recently, various research groups re-evaluated these older 
antimalarial 4(1H)-quinolones, 4(1H)-pyridones, and its’ derivatives – endochin 
(7), clopidol (8), ICI56,780 (9), and floxacrine (10) – which shed light to the 
possibility that they can be viable leads if improvements to their physicochemical 
properties are successfully accomplished (Figure 4).
To improve physicochemical properties, it is necessary to scrutinize the proper-
ties, such as molecular weight, polar surface area, rotatable bonds, hydrogen bond 
acceptors and hydrogen bond donors as introduced in Lipinski’s paper introducing 
Rule of Five and other subsequent papers [27, 28]. Another key feature to consider 
is the complexity of the molecule via Fsp3, which measures saturation of the 
Figure 3. 
4(1H)-quinolone and 4(1H)-pyridone scaffold.
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compound. It has been observed that increase saturated carbons leads to higher 
aqueous solubility – a major downfall in 4(1H)-quinolone and 4(1H)-pyridone type 
molecules [29].
2.1 4(1H)-pyridones
2.1.1 Optimization of clopidol
An anticoccidial drug clopidal (8) was discovered to possess antimalarial activ-
ity in the 1960s by the Walter Reed Army Institute of Research. Assays presented 
activity towards four strains of Plasmodium spp. – P. berghei, P. gallinaceum, P. 
cynomologi, and P. falciparum [25, 30].
After several decades, scientists at GlaxoSmithKline (GSK) exerts efforts to opti-
mize clopidal (8) due to emerging evidence that 8 may employ similar cytochrome 
bc1 inhibition, like atovaquone (6) [31]. They hypothesize that clopidal (8) acts as 
a ubiquinone-mimic; therefore, replacing C-3 chlorine with a lipophilic sidechain. 
Installing an n-octyl chain improved in vitro activity (IC50 = 4 μM) but diminished 
in vivo activity (ED50 ≥ 60 mg/kg). They hypothesized that the difference in activ-
ity may be due to metabolic degradation of the alkyl chain. To resolve this issue 
regarding the chemically labile sidechain, they installed the trans-(4-chlorophenyl)
cyclohexyl sidechain of atovaquone (6), known to be resistant to metabolism, 
which significantly increased both in vitro and in vivo activity (IC50 = 0.05 μM; 
ED50 = 0.6 mg/kg). This led to the study of biaryl analogues, where 4-phenoxyphe-
nyl sidechain also exhibited similar in vitro and in vivo activity. More in-depth SAR 
study was performed on 5-(phenoxyphenyl)-4(1H)-pyridones (Figure 5) [32].
Figure 5. 
Initial optimization of clopidol.
Figure 4. 
Original 4(1H)-pyridones, 4(1H)-quinolones, and its’ derivatives with antimalarial activity.
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Variations to the C-2, C-3, and C-6 position were made and further improve-
ments could not be observed (Figure 6). Variations on the aryl group made a 
major impact on the in vitro activity. This led to GW308678 (11) and GW844520 
(12), where 12 entered preclinical trials [32]. However, after observing mild and 
reversible histopathological findings in skeletal and cardiac muscles, this study was 
abandoned. They hypothesized that these findings were due to its high lipophilic 
nature and long half-life. Therefore, they sought to improve the physicochemical 
properties [25].
To improve the physicochemical properties of GW844520 (12), the scientists 
at GSK introduced a hydroxymethyl group on C-2 position that significantly 
diminished the activity (IC50 = 0.13 μM). Interestingly, its isomer with the hydroxy-
methyl group on the C-6 position maintained high level of antimalarial activity 
(IC50 = 0.005 μM) with improved solubility. Simultaneously, a prodrug approach was 
introduced to optimize solubility. The newly introduced hydroxy group offered more 
chemically stable prodrugs than previous attempts utilizing the C4-OH. This led to 
GSK932121 (13) and a phosphate ester prodrug of 13, where it was selected to enter 
human trials. Regrettably, this study was terminated due to toxicological findings 
from lack of species-specific target selectivity of the parent drug (Figure 7) [25, 33].
Recently, various linkers and heteroaromatic rings have been investigated. 




Overall optimization scheme of clopidol.
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flexible linker (ether and alkane) counterparts, their potency decreases by a 
ten-fold. They anticipate that the flexibility allows the compound to mold into the 
active site with correct hydrophobic interactions. Another observation was that 
replacing the proximal phenyl ring with a pyridine ring maintains the activity and 
improves pharmacokinetic profiles. This demonstrates the potential of analogues 
of 13 in hopes of improving pharmacokinetic and toxicology profiles of 4(1H)-
pyridones [34].
2.2 4(1H)-quinolones
With renewed efforts to optimize 4(1H)-quinolones, three main factors are con-
sidered –aqueous solubility, resistance index (RI), and potency. Aqueous solubility 
is essential in developing a dose-proportional pharmacokinetic profile for orally 
administered drugs. The RI is the ratio of the effective concentration to kill 50% of 
the parasite population of two clinically relevant malaria strains, where one is the 
parent or sensitive strain. For instance, W2 and TM90-C2B are frequently used, 
where W2 is the multi-drug resistant strain that is atovaquone-sensitive and TM90-
C2B is atovaquone-resistant due to a point mutation in cytochrome b. Given this, RI 
would be the EC50 of TM90-C2B divided by the EC50 of W2 [35]. Ideally, this value 
is 1, which demonstrates that the drug is equally potent against both malaria strains; 
values between 0.3 and 3.0 are acceptable. Finally, low nanomolar potency of both 
strains is preferred.
The balance amongst these three qualities are necessary for the development of a 
potent, orally bioavailable antimalarial quinolones.
2.2.1 Optimized of floxacrine
In 1974, an evaluation of floxacrine (10) for antimalarial activity was performed. 
It was discovered that 10 exhibited casual prophylactic activity. However, it had 
several liabilities – cardiovascular toxicity, parasite drug resistance, and poor aque-
ous solubility [36, 37]. Efforts have been made to synthesize analogous compounds 
devoid of these drawbacks. In the 1990s, WR243251 (14), a 1,2,3,4-tetrahydroacri-
din-9(10H)-ones (THAs), was discovered and did not display any cardiovascular 
toxicity (Figure 8) [37]. However, it still displayed resistance and had poor aqueous 
solubility [37, 38].
Due to limited exploration of THAs since the discovery of WR243251, Manetsch 
and Kyle initiated a structure–activity relationship (SAR) and a structure–property 
relationship (SPR) studies to better understand THAs and its ability to exert activity 
towards both the blood and liver stage of the parasite.
Altering the number of carbons on the saturated ring system significantly 
reduced the activity and the aqueous solubility. Here on out, the scientists modified 
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ring. It became evident that the 6- and 7-position are key positions for antimalarial 
activity, which also affected the RI. The electronics on the 6-position did not 
significantly alter the activity. However, the 7-position was more sensitive, as it 
displayed preference for electron donating groups to retain potency and maintain 
the RI between 0.3 and 3. Furthermore, an inverse relationship was observed 
between potency and aqueous solubility. Substituting either or both the 5-position 
and 8-position, decreased activity and increased solubility. With this, THA-114 
(15) and THA-115 (16) were found to exhibit nanomolar antimalarial activity with 
an acceptable RI that lacks toxicity. However, its solubility did not fall within the 
acceptable range of 40 μM or greater (Figure 9). Developing a candidate that is 
both active and has optimal physicochemical properties is difficult; nonetheless, 
it is necessary. The inability to develop such molecules leads to issues with in vivo 
efficacy studies and hinders with safety assessment studies [39].
2.2.2 Optimization of ICI56,780
Scientists at Imperial Chemical Industries (ICI) developed ICI56,780 (9) as an 
antimalarial agent. What was striking about this compound series was its activity 
against blood stage and liver stage parasites in P. cynomolgi in rhesus monkeys and 
P. berghei in mice. However, disappointingly, resistance was developed in P. berghei 
after one passage [40, 41].
Manetsch and Kyle initiated work on SAR to optimize 9. ICI56,780 (9) was 
utilized as the reference molecule, where they observed excellent potency for 
both W2 and TM90-C2B and in vitro liver stage activity; however, the potential 
to observe cross–resistance with atovaquone was high. Examination of the 2-, 3-, 
6-, and 7-position concluded that the original 6- and 7- substituents are optimal. 
3-position was rather interesting. Alteration significantly decreased the activ-
ity; however, remained within acceptable range. Interestingly, the RI fell into 
an appropriate range. Finally, the 2-position was examined with and without a 
methyl group, where the analogue with the methyl group displayed higher potency. 
This led to PEQ-1020 (17) an PEQ-437 (18). With promising in vitro blood stage 
data, compound 17 were tested in vivo. The insoluble nature of the compound 17 
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Given the necessity to improve aqueous solubility, ionizable piperazinyl-
substituted analogues were developed. The linker length between the pipera-
zine moiety and the benzenoid ring was investigated, along with the various 
piperazinyl-substituent. Ethylene linker analogues were found to diminish blood 
stage activity, while methylene linker analogues were most active. Amongst the 
N-phenylpiperazinyl, N-benzylpiperazinyl, and p-methoxybenzylpiperazinyl sub-
stituents, N-phenylpiperazinyl was most potent. When the piperazinyl-substituent 
was placed on the 6-position rather than the 7-position, the analogues were void 
of activity. Based on previously developed analogues, 3-position was investigated. 
Similarly, 3-halo substituted analogs improved RI; however, diminished activity 
compared to that of the methyl ester at the 3-position. This led to the discovery of 
32 and due to its high potency against in vitro liver stage activity, 32 was further 
evaluated in an in vivo assay against liver stage. Compound 32 was able to generate 
cures at oral doses of 25 mg/kg or higher [44].
2.2.3 Optimization of endochin
Endochin (7) was discovered during World War II by Hans Andersag, a German 
chemist from Bayer [45, 46]. This compound had been identified to be a causal 
prophylactic and potent erythrocytic stage agent in avian models [47]. However, it 
was deemed ineffective against human malaria due to its physicochemical proper-
ties and its inactive metabolite that formed in the presence of cytochrome P450 
(CYP450) enzymes [45]. This had inspired research teams, like the one of Manetsch 
and Kyle or Riscoe, to diversify such molecule.
The two groups worked together to synthesize a series of compounds, termed 
ELQ for endochin-like quinolones and P4Q for phenyl/aryl substituted in the 4-posi-
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substituent on the 3- or 7-position, it was determined that the 3-position is essential 
to the activity of endochin. Because the alkyl chain on the 3-position was metaboli-
cally labile, they modified the 3-position. By diversifying the 3-position, it suggested 
that the active site was hydrophobic with a reasonably sized pocket. The substituents 
on the benzenoid ring was also investigated, where installing a chlorine at the 6-posi-
tion and a methoxy- group on the 7-position increased potency through the nature 
of electronics. The chlorine increases the binding affinity by increasing the acidity of 
N-H. The methoxy-group increases the potential of the carbonyl to accept hydrogen 
bonds with the active site. Substitutions at the 5- and 8-positions were not tolerated 
well. To optimize variably in the SAR study, further studies utilized 3-alkylphenyl-
4(1H)-quinolones. It was revealed that para position observed higher activity, para 
and ortho position had acceptable RI, and ortho position exhibited the higher aqueous 
solubility. Of this series, P4Q-146 (19) and P4Q-158 (20) were the compounds with 
the best characteristics – single-digit nanomolar activity with acceptable RI and lack 
of toxicity. To further optimize the aryl-substituent, moieties with two aromatic 
rings were investigated, where some were inspired by the GSK pyridones. This 
led to P4Q-390 (21). P4Q-391 (22), and ELQ-300 (23), where they exhibited low 
single-digit nanomolar activity with acceptable RI (Figure 11). P4Q–391 (22) and 
ELQ-300 (23) are especially unique because of its activity against exo-erythrocytic 
stage, which includes liver schizonts, gametocytes, and ookinetes and oocytes. 
Antimalarials that are capable of preventing the transmission of malaria is extremely 
important. For this reason, ELQ-300 (23) was selected by Medicines for Malaria 
Venture (MMV) to undergo preclinical development, where it resulted in causal pro-
phylaxis in mice malarial models and complete inhibition of oocyst formation. Unlike 
the structurally similar GSK 4(1H)-pyridone, 23 was a species–specific inhibitor. 
However, due to the poor solubility of this compound, a proper safety margin could 
not be established and was, therefore, abandoned for future tests [48–54].
Figure 11. 
Optimization of endochin to ELQ-300.
Plasmodium Species and Drug Resistance
12
2.2.4 Optimization of TDR molecules
The Guy laboratory is also one of the various groups that are working to opti-
mize quinolones to develop a potent antimalarial; however, their approach was 
slightly different. Rather than utilizing the older antimalarials, this group utilized 
two compounds that had confirmed antimalarial activity through the WHO’s 
Special Programme for Tropical Disease Research (TDR). TDR42098 (24) and 
TDR17516 (25), differing in the position of the methoxy group on the benzenoid 
ring, was identified and confirmed to have antimalarial activity from a screening 
campaign by TDR at Tibotec using 17,472 non-proprietary compounds sourced 
from SPECS (Figure 12) [55].
Utilizing 24 and 25 as the reference compound, the Guy laboratory modified the 
2-, 3-, 5-, and 7-position to see its effect on the activity, solubility, and permeability. In 
the first series of compounds, the 3-position was investigated. Removal of the car-
boxyl ester resulted in the total loss of activity and solubility for both analogues of 24 
and 25. Replacing the carboxylate with either an acid or amide also resulted in the total 
loss of activity and due to its hydrophilic nature, loss of permeability was observed. 
In the next series, quinoline analogues were investigated, where any alterations to the 
4-oxo observed total loss of activity. It is possible that the ability for the quinolones 
to undergo tautomerization is a necessary characteristic to have antimalarial activity. 
Finally, they investigated the 2-position by installing varying aryl groups. Alterations 
of analogue 25 at the 2-position diminished antimalarial activity; however, analogues 
of 24 observed different results. Installing an unsubstituted phenyl group decreased 
activity by approximately two-fold, while maintaining solubility and increasing 
permeability. Ortho substituted phenyl rings diminished any activity. Para substituted 
phenyl rings either decreased activity by four-fold or completely, in addition to signifi-
cant decrease in aqueous solubility. Meta substituted rings observed the best potency 
with acceptable aqueous solubility and increased permeability (Figure 13) [56].
Findings from the initial SAR study prompted the Guy laboratory to further 
investigate 3-carboxy-4(1H)-quinolones. Various meta substituted phenyl rings were 
installed to the 2-position. Introduction of hydrophobic groups, such as methyl, 
vinyl, and phenyl, retained similar potency to 24. Installation of alkoxy groups 
on the meta position displayed great improvement to the potency. Strong electron 
withdrawing groups, such as nitro, acetyl, and methyl sulfonyl, and H-bond donors 
Figure 13. 
Initial optimization of TDR molecules.
Figure 12. 
TDR molecules identified as compounds with antimalarial activity.
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resulted in loss of activity. This suggests that hydrophobic electron-donating group 
on the meta-position of the phenyl group is most ideal; however, like other quino-
lones, increasing activity with hydrophobic substituents tends to decrease aqueous 
solubility and permeability – essential characteristics for oral bioavailability [57].
7-position was also investigated, where findings also displayed that small hydro-
phobic electron-donating group improves potency, while an electron withdrawing 
group diminishes the potency [57].
Multi-substituted benzenoid ring was investigated to observe if there are any 
synergistic effect of varying substituents. 5,7- and 6,7- dihalogenated compounds 
were inactive towards multidrug-resistant (MDR) strains. Similar results were 
observed from 6,7-dimethoxy analogues. Simultaneous incorporation of a methoxy 
and halo group was investigated, where it exhibited sub-micromolar to nanomolar 
activity when the halogen was on the 6 position and the methoxy was on the 7 
position. When installing a methoxy group on the 6 position and the halogen on the 
7 position, antimalarial activity against all strains were lost [57].
Finally, the carbonyl substituent on the 3-position was investigated. Varying 
chain lengths and incorporation of morpholinyl, pyrrolidinyl, and N,N-dimethyl 
amino functionalities were installed; however, these changes reduced potency 
without any increase in solubility of the compounds (Figure 14) [57].
13 compounds that had an appropriate balance amongst activity, solubil-
ity and permeability were selected by the Guy laboratory to test for microsomal 
activity. Compounds 26 and 27 displayed the most promising liver microsomal 
activity (CLint,in vitro < 4 uL/min/mg in human and mouse microsomes). These two 
compounds also displayed highest Cmax and AUC, which is indicative of extensive 
systemic exposure after oral administration. This was observed in in vivo antima-
larial activity assay, where these two compounds were the only compounds that 
suppressed parasite growth (Figure 15) [57].
2.2.5 Optimization of HDQ
Similar to the Guy laboratory, the O’Neill and Ward utilized a unique approach 
that led them to study quinolones to treat malaria. Originally, hydroxy-2-dodecyl-
4(1H)-quinolone (HDQ , 28) was known to be active against alternative NADH 
Figure 14. 
Recent optimization of TDR molecule by the guy lab.
Figure 15. 
Overall optimization of TDR molecule to frontrunner compounds.
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dehydrogenase from the fungus Yarrowia lipolytica (Figure 16). In 2007, HDQ (28) 
exhibited nanomolar activity against P. falciparum and T. gondii [58]. This led 
O’Neill and Ward to perform various chemoinformatic methods (molecular fin-
gerprinting, turbo similarity, principal component analysis, Bayesian modeling, 
and bioisosteric replacements) to select compounds for high-throughput screen-
ing. 17,000 compounds were selected from a commercial library of approximately 
750,000 compounds from Biofocus DPI. Afterwards, these molecules were sub-
jected to a sequential high-throughput screening method utilizing an in vitro assay 
against recombinant PfNDH2. This led to the selection of quinolone core as the 
main target chemotype for their SAR study [59–61].
Quinolones with 2-substituted monoaryl were selected as the template, as it 
contained a lipophilic side chain that was not metabolically labile like the aliphatic 
chain on HDQ (28) [59–61].
Initially, the quinolone core was modified. Installing a 8-aza-4(1H)-quinolone 
core reduced antimalarial activity. Similar to the previous optimization of various 
quinolones, chlorine and fluorine is well-tolerated, methoxy on the 7-position 
is well-tolerated, and large substituents on the benzenoid ring is not well toler-
ated. Interestingly, unsubstituted 3-position provides a slight increase in activ-
ity; however, this small advantage is outweighed by the decrease in solubility. 
Given that there is a large hydrophobic pocket at the active site, these researchers 
investigated 2-substituted biaryl quinolones. It became clear to the researchers 
that a monoaryl group could not obtain an IC50 of below 500 nM. Investigation of 
the biaryl began with modification of the linkers. Variations on linkers (p-CH2, 
m-CH2, and p-O) did not affect the activity of the compound, as they were all 
well-tolerated. The terminal substituent on the distal phenyl group is also depen-
dent on the other substituents on the molecule. In general, OCF3 is the optimal 
terminal group, while a large EWG was less tolerated. This led to the discovery 
of CK-2-68 (29). Due to poor solubility, the use of prodrug moiety and altering 
formulations provided a proof of concept that CK-2-68 (29) clears the parasites in 
vivo [59–62].
To improve solubility properties, heterocyclic substituents were introduced 
to the quinolone core. It was observed that the distal ring is most favorable as a 
phenyl ring; however, a pyridine ring for the replacement of the proximal aro-
matic ring demonstrates great potency, reduced ClogP, and improved solubility. 
However, even with the improved solubility, the in vivo testing had to utilize a 
prodrug moiety to establish a proof of concept that 30 does clear the parasites 
in vivo [60].
The most recent attempt to improve solubility was to utilize a bioisostere of ben-
zene rings. Pyrazoles have been well-documented to improve solubility by reducing 
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3. Conclusion
While malaria remains to be a global health threat, developing a novel class 
of drugs has become essential to treat and prevent the spread of this disease. 
4(1H)-quinolones and 4(1H)-pyridones both display potential of developing into 
potent antimalarial agents due to recent re-evaluation of old 4(1H)-quinolones 
and 4(1H)-pyridones possessing antimalarial activity. These historical quinolones 
display promising activity against both erythrocytic and exo-erythrocytic stages of 
the parasite. Various research groups invested their efforts and resources to opti-
mize these 4(1H)-pyridones or 4(1H)-quinolones since it is perfect for the malaria 
eradication initiative.
The frontrunner compound for 4(1H)-pyridone is 13, which displayed single-
digit nanomolar activity against the erythrocytic stage with excellent solubility. 
However, after entering first-time in human study, 13 displayed toxicity, which 
terminated the study.
Unlike 4(1H)-pyridones, 4(1H)-quinolones (P4Qs, ELQs, THAs, TDR analogues, 
and HDQ analogues) lack cytotoxicity. This is essential to develop a species-specific 
inhibitor. The frontrunner compounds for ELQ/P4Q are 22 and 23, which displayed 
low nanomolar activity for both the erythrocytic and exo-erythrocytic stages. In addi-
tion to this, 22 and 23 displayed activity against the transmitting stages, making these 
molecules especially important. The frontrunner compounds for PEQ are 17, 18, and 
32, which displayed low nanomolar activity for both the erythrocytic and liver stages. 
Another molecule that is promising. The frontrunner compounds for THA are 15 and 
16, which displayed nanomolar activity for the erythrocytic stage. The frontrunner 
compound for TDR analogues are 26 and 27, which displayed nanomolar activity for 
the erythrocytic stage. The frontrunner compound for HDQ analogues are 30 and 31, 
which displayed nanomolar activity for the erythrocytic stage.
Figure 17. 
Optimization of HDQ .
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Since many research teams focus solely on the activity against the blood stage, 
compounds 22, 23, 17, 18, and 32 are especially promising, as these display exo-
erythrocytic activity, along with the erythrocytic activity.
Nevertheless, one major downfall with the development of 4(1H)-quinolones 
and 4(1H)-pyridones is the poor aqueous solubility. This prevents proper develop-
ment of pharmacokinetic profiles for drug candidacy; therefore, failed clinical 
development and development was halted in the early 80s.
Thankfully, by early 2000s, the field of medicinal chemistry advanced, where 
researchers could optimize historical quinolones to develop them into drug-like 
molecules. Even with the variety of chemotypes, the approach towards optimiza-
tion is quite similar amongst the various research teams.
Despite these obstacles, 4(1H)-quinolones have a great potential of becoming 
the next class of antimalarials. These molecules lack toxicity and have acceptable 
physicochemical properties, aside from solubility. With increased understanding 
to improve aqueous solubility, it is recommended to continue research on anti-
malarial quinolones, as they have great potential of becoming orally bioavailable 
antimalarials.
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